Nigeria Toxicity A B S T R A C T Background: Tuberculosis (TB) could be fatal if left untreated, however, adverse effects of anti-TB medications (anti-TBs) themselves may limit treatment. We determined the incidence and clinical characteristics of hepatotoxicity in hospitalized patients receiving first-line anti-TB treatment.
Introduction
Tuberculosis (TB) is one of the most common infectious diseases and there were an estimated 9 million incident cases worldwide according to the global tuberculosis report of 2014 [1] . Since the scale-up of nationwide directly observed treatment (DOTS) in 2002 in Nigeria, a total of 640,113 of all forms of TB have been registered, with 90,447 notifications (400/100,000 population) in 2008 alone [2] . The first line regimen which requires administration of a combination of anti-TB medications (anti-TBs) for 6-9 months achieved a treatment success rate of about 84%, a death rate of 5%, and a defaulter rate of 8% in Nigeria [2] . The DOTS program, which has established or strengthened linkages with tertiary hospitals in recent years, is the major provider of TB treatment using the standard short course chemotherapy [2] .
Adverse drug reactions to anti-TBs could lead to treatment interruptions with resultant poor outcomes, including the risk of drug resistance [3] . Hepatotoxicity is one of the most important adverse drug reactions associated with anti-TBs [4] , and depending on the definition of hepatotoxicity, the incidence range is from 2% to 28% [5] . Although it may be challenging to predict when hepatotoxicity will occur, it is known that certain patient characteristics put them at higher risk. These include hepatic abnormalities, like chronic hepatitis B virus and hepatitis C virus (HCV), disseminated TB, Asian ethnicity, female sex, significant alcohol use, concurrent administration of other hepatotoxic medications, being elderly, and being malnourished [6] [7] [8] [9] . Although human immunodeficiency virus (HIV)/AIDS is significantly associated with development of hepatotoxicity [10] , the reason for this association is obscure. However, this may be as a result of excessive immune activation leading to less efficient handling of oxidative stress and detoxification of drug metabolites [11] .
The advantage of regular monitoring of liver function test (LFT) in patients receiving anti-TBs, especially in countries where health budgets are meagre, has not been clearly established. However, the prevention or early detection of hepatotoxicity is important as morbidity and mortality can be substantial among those with symptomatic hepatotoxicity. Some guidelines only emphasize clinical monitoring while others additionally recommend routine biochemical monitoring at varying frequencies among the high risk groups [12, 13] . Although there are attempts to improve the quality of patient care under DOTS, data on anti-TB hepatotoxicity in Nigeria, whether clinical or biochemical, are scarce. We describe the incidence and the clinical and laboratory characteristics of hospitalized patients receiving anti-TBs who developed hepatotoxicity at the Jos University Teaching Hospital (JUTH), Jos, Nigeria.
Materials and methods
This was a retrospective cohort study of new TB cases aged P18 years seen at the infectious diseases wards of JUTH from January 2013 to June 2013 who were receiving first line anti-TBs. Data were retrieved from the case notes of all of the 110 patients seen in that period who met the inclusion criteria. Usually, all patients starting anti-TBs have baseline LFT done, however, it is only repeated in those who developed hepatotoxicity or if there are other indications. The data collected included: socio-demographic data (age, sex, and alcohol consumption), features of symptomatic hepatotoxicity (including fatigue, loss of appetite, nausea, vomiting, right hypochondrial pain/tenderness, fever, and jaundice), pulmonary or extrapulmonary TB, HIV status, combination antiretroviral therapy (cART) status, and body mass index (BMI; kg/m 2 ). Laboratory data included alanine transaminase (ALT; IU/L), aspartate transaminase (IU/L), total and conjugated bilirubin (lmol/L), total serum protein and albumin (g/L), hepatitis B surface antigen (HBsAg), and HCV antibody (anti-HCV).
Diagnosis of TB was based on Ziehl-Neelsen sputum smear microscopy, GeneXpert assay, or any combination of clinical and radiological/pathological evidence. Hepatotoxicity was defined as: (1) any combination of newly developing or worsening features of symptomatic hepatitis with a temporal relationship to anti-TB initiation without an apparent alternative explanation; (2) a stricter increase in serum ALT >3 times upper limit of normal (ULN) together with features of symptomatic hepatitis according to the American Thoracic Society (ATS) [13] . This is a part of the ATS definition which also considers ALT >5 times ULN in the absence of symptoms as hepatotoxicity. Our laboratory normal reference for both ALT and aspartate transaminase was <40 IU/L, and <17 lmol/L for total bilirubin. All admitted patients are routinely reviewed and the diagnosis of hepatotoxicity was made by at least a specialty registrar.
We also excluded those who were not prescribed a standard anti-TB regimen or who were already on anti-TBs before hospital admission. Standard anti-TB regimen is: isoniazid, rifampicin, ethambutol, and pyrazinamide with dosages decided according to the weight of the patient [2] . Ethical approval was obtained from the JUTH Ethics Committee.
Statistical analyses
Analyses were carried out using Stata software version 10.0 (Stata Corporation, College Station, TX, USA). The main outcome variable was hepatotoxicity (symptomatic hepatitis ± ALT >3 Â ULN).
Baseline characteristics of the 110 patients were described and the characteristics of patients with symptomatic hepatitis were compared with those without. Continuous variables were presented as mean (standard deviation [SD]) or as median (interquartile range [IQR]) while the categorical variables were presented as proportions. Chi-square test or Fisher's exact test was used to determine the association between each categorical variable and the outcome. Comparisons between two means or between two medians were done using unpaired t test or Mann-Whitney test. A p value <.05 was considered significant for all tests.
Results
The baseline characteristics of all 110 patients are shown in Table 1 . There were 20 (18.2%) patients who developed symptomatic hepatotoxicity, in which 10 (50%) manifested with jaundice as part of the features of hepatotoxicity. Furthermore, 18 (16.4%) of the 20 patients met the stricter criteria for hepatotoxicity. Therefore, the cumulative incidence of hepatotoxicity based on clinical features alone was 18.2%, whereas it was 16.4% according to the ATS criteria.
The characteristics of the 20 (18.2%) patients who developed symptomatic hepatotoxicity are compared with those who did not in Table 2 . The median age of patients with hepatotoxicity was slightly lower than that of those without hepatotoxicity, although this difference was not significant, 35 (IQR 27-43) years vs. 37 (IQR 30-45) years; p = .34. Although the proportion of females (10, 50%) was higher among those with hepatotoxicity versus those without (40, 44%), the difference was not significant; p = .65. Similarly, the higher mean BMI of those with hepatotoxicity (18.8 kg/m 2 , SD 3.4) was not significantly different from those without hepatotoxicity (18.4 kg/m 2 , SD 3.8), p = .70. The median duration of anti-TB treatment was the same for those with hepatotoxicity compared with those without, 14.0 days (IQR 9-36) vs. 14 days (IQR 9-39), p = .60. Similarly, there was no significant difference between those with/without hepatotoxicity in HIV positive status (65% vs. 70.8%; p = .61), those on cART (55% vs. 52.8%; p = .86), alcohol consumption (35% vs. 32.6%; p = .84), HBsAg positivity (7.2% vs. 11.4%; p = .35), and HCV antibody positivity (0% vs. 2.9%; p = > .99). Counterintuitively, those who did not have hepatotoxicity in the course of treatment had significantly higher baseline median ALT IQR (67 vs. 35 ; p = .04) and bilirubin: median total IQR (20.4 [20.4-20.4] 
Discussion
We found an incidence of symptomatic hepatotoxicity of 18% and a 16% incidence according to the ATS [13] . Makhlouf et al. [14] similarly reported an incidence of 15%, but among outpatients in Egypt. However, some investigators in Africa and Asia found comparatively lower incidence of between 4% and 11.5% [15] [16] [17] [18] . By contrast, Yimer et al. [19] found a higher prevalence of 30%, probably because the majority of patients in their study were likely to have experienced the combined hepatotoxic effects of anti-TBs and cART, compared with only about 50% of patients receiving cART in the current study.
Variations in the reported rates of hepatotoxicity are also likely as a result of differences in study design, patient characteristics, diagnostic criteria for hepatotoxicity, and concurrent use of hepato-protective therapy with anti-TBs. Although the mean BMI of patients with hepatotoxicity of 18.8 kg/m 2 was not significantly different from 18.4 kg/m 2 in those without hepatotoxicity, low BMI is generally a recognized risk factor for hepatotoxicity [8] . Problems with drug absorption in wasted patients with advanced HIV/AIDS and the imprecise, but practical, anti-TB dosing based on weight bands might have confounded our findings. The median time to the development of hepatotoxicity was 14 days (IQR 9-36 days). This finding differs from those of other studies, although with some overlap, which reported a median of 28 days and a range between 14 and 60 days [16, 17] . The observed difference could have arisen because we followed our patients only while in hospital, a generally shorter period of follow up compared with the 14-60 days it took for most cases of hepatotoxicity to occur [16, 17] . Some studies found older age as a risk factor for hepatotoxicity [8, 20, 21] . However, our study, like some others [7, 20, 21] , did not find an association. The probable reason is that our cohort is predominantly young where the median age is <40 years. We did not find sex and BMI to be associated with hepatotoxicity. Similar findings were previously reported [13, 14, 22] . Nonetheless, females were thought to be at an increased risk due to their lower BMI and slow acetylator status [23, 24] .
Coinfection with hepatitis B virus, HCV, or HIV was not found to be associated with hepatotoxicity in the current study. Several other studies had clearly indicated that they were risk factors for anti-TB hepatotoxicity [13, 22, 23] . However, there was only one patient with HBsAg and none with anti-HCV antibody among those with hepatotoxicity in the current study. Our study also did not find concomitant antiretroviral therapy or alcohol consumption to be associated with hepatotoxicity. Hussain et al. [24] also did not find alcohol as a significant risk factor. This is at variance with studies that found them to be important risk factors for hepatotoxicity [23, [25] [26] [27] . Surprisingly also, ALT and bilirubin were significantly higher in those without hepatotoxicity. Although abnormal baseline LFT is predictive of anti-TB hepatotoxicity [28] , differences in abilities of individuals to activate adaptive liver-protective mechanisms aimed at ameliorating effects of exposure to hepatotoxic agents [29] may partly explain our finding. In addition, data on concurrent use of other hepatotoxic medications or pre-existing liver disease were not assessed in the present cohort.
The present study has important limitations. Our findings may not be widely generalizable as the data emanated from a relatively few patients who were hospitalized in a single tertiary hospital. The estimation of incidence was based on symptomatic hepatotoxicity. Because LFT is not routinely repeated following initiation of anti-TBs, patients with asymptomatic hepatotoxicity [13] might have been missed. It was therefore also not possible to determine if this group of patients were at increased risk of progressing to the more clinically relevant overt hepatotoxicity.
Conclusions
The incidence of symptomatic hepatotoxicity among our hospitalized patients is high and ALT levels were mostly in excess of 3 times ULN among cases. While doubts about the utility of LFT in preventing or detecting hepatotoxicity may exist, close clinical and laboratory monitoring are important in hospitalized patients. Appropriately designed studies to determine the rates of both symptomatic and asymptomatic anti-TB induced hepatotoxicity and their predictors are needed in our environment.
